Floatz logo

Recombinant Fowlpox-Cea/Tricom Vaccine

Metastases, Neoplasm

National Cancer Institute (NCI)vaccinePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Metastases, Neoplasm cohort.

Asset / SponsorPhaseRating
Abi-007
Celgene Corporation
Phase 3BB
MOTEXAFIN GADOLINIUM HYDRATE
Phase 3BB
Dimesna
BioNumerik Pharmaceuticals, Inc.
Phase 3BB
Lonafarnib
Merck Sharp & Dohme LLC
Phase 3B
Fludarabine
Jonsson Comprehensive Cancer Center
Phase 1/2B

View all 19 →

Same molecule, other indications

Recombinant Fowlpox-Cea/Tricom Vaccine is also rated in:

Breast CancerDormant
CC
Indicative ·
47 / 100
View asset →
Recurrent Colon CancerDormant
CC
Indicative ·
44 / 100
View asset →
Recurrent Rectal CancerDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →